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Abstract: Half of human cancers harbor TP53 mutations that render p53 inactive as a tumor suppressor.
In these cancers, reactivation of mutant p53 (mutp53) through restoration of wild-type-like function
constitutes a valuable anticancer therapeutic strategy. In order to search for mutp53 reactivators,
a small library of tryptophanol-derived oxazoloisoindolinones was synthesized and the potential of
these compounds as mutp53 reactivators and anticancer agents was investigated in human tumor
cells and xenograft mouse models. By analysis of their anti-proliferative effect on a panel of p53-null
NCI-H1299 tumor cells ectopically expressing highly prevalent mutp53, the compound SLMP53-2 was
selected based on its potential reactivation of multiple structural mutp53. In mutp53-Y220C-expressing
hepatocellular carcinoma (HCC) cells, SLMP53-2-induced growth inhibition was mediated by cell
cycle arrest, apoptosis, and endoplasmic reticulum stress response. In these cells, SLMP53-2 restored
wild-type-like conformation and DNA-binding ability of mutp53-Y220C by enhancing its interaction
with the heat shock protein 70 (Hsp70), leading to the reestablishment of p53 transcriptional activity.
Additionally, SLMP53-2 displayed synergistic effect with sorafenib, the only approved therapy for
advanced HCC. Notably, it exhibited potent antitumor activity in human HCC xenograft mouse
models with a favorable toxicological profile. Collectively, SLMP53-2 is a new mutp53-targeting
agent with promising antitumor activity, particularly against HCC.
Keywords: anticancer therapeutics; hepatocellular carcinoma; Hsp70; mutant p53; tryptophanol-derived
oxazoloisoindolinone
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1. Introduction
As the most frequently inactivated tumor suppressor in human tumors, p53 has attracted great
interest as an anticancer therapeutic target. p53 is a transcription factor that regulates several cellular
processes, including apoptosis, cell cycle, and DNA-damage repair [1]. Over half of human tumors
harbor TP53 mutations, leading not only to the impairment of p53 tumor-suppressive activity, but also
to gain-of-function that promotes tumor growth, dissemination, and chemoresistance [2]. Most p53
mutations occur within the DNA-binding domain (DBD). The amino acid substitutions in mutant p53
(mutp53) may lead to substantial protein unfolding (structural mutations; e.g., R175H, Y220C, G245S),
or to loss of DNA contacts, with no significant structural destabilization (contact mutations; e.g., R280K,
R273H) [2,3]. Regardless of the type, mutp53 loses transcriptional, and therefore tumor-suppressive,
activity. Hence, restoring wild-type (wt)-like activity to mutp53 is an appealing anticancer therapeutic
strategy. In fact, extensive efforts have been made in the search for mutp53 reactivators [4]. Among the
mutp53 reactivators disclosed to date, distinct molecular mechanisms have been reported. While some
reactivators bind to mutp53, others display indirect reactivation mechanisms by targeting proteins like
heat shock protein 40 (Hsp40), which promotes mutp53 refolding and subsequent re-establishment of
DNA-binding ability [5]. Although several small molecule mutp53 reactivators have been reported to
date, only APR-246 (PRIMA-1MET) and COTI-2 are currently undergoing clinical trials [5].
Primary liver cancer presented the sixth highest incidence worldwide in 2018 [6], which is
predicted to increase in the upcoming years [7]. Hepatocellular carcinoma (HCC), the most common
histologic type of primary liver cancer, is associated with unfavorable prognosis, mainly due to high
chemoresistance and recurrence rates [8,9]. The majority of patients are diagnosed at advanced-or
terminal-stage, and available therapeutic options are restricted to symptomatic treatment or sorafenib,
a multi-target kinase inhibitor [8,9]. Nonetheless, the increase of median overall survival of HCC
patients treated with sorafenib is only 2.8 months [8], making the identification of effective therapeutic
alternatives a high priority. About 30% of HCC harbor p53 mutations, correlating with increased
invasiveness, recurrence, and lower survival rates [10,11]. This makes mutp53 a privileged therapeutic
target in HCC. Herein, we unveil the new mutp53 reactivator SLMP53-1 with great potential as
an anticancer agent, particularly against HCC.
2. Results
2.1. SLMP53-2 Displays mutp53-Dependent Growth Inhibitory Effect in Human Tumor Cells, Leading to Cell
Cycle Arrest, Apoptosis and Endoplasmic Reticulum (ER) Stress
In our previous work, the tryptophanol-derived oxazoloisoindolinone SLMP53-1 was identified
as a reactivator of mutp53-R280K with in vivo p53-dependent anti-tumor activity [12]. In order
to search for new mutp53 reactivators, a small library of SLMP53-1 derivatives was synthesized.
The activity of the compounds as potential mutp53 reactivators was investigated by analysis of their
anti-proliferative effect on p53-null NCI-H1299 tumor cells ectopically expressing four prevalent
mutp53 forms. By sulforhodamine B (SRB) assay, the compound SLMP53-2 (Figure 1A) was selected
based on its marked reduction of the IC50 values in NCI-H1299 cells expressing mutp53-R175H, -Y220C,
or -G245S, compared to cells transfected with the empty vector (Figure 1B). These results evidenced the
ability of SLMP53-2 to reactivate multiple structural mutp53. Interestingly, they also showed a distinct
selectivity of SLMP53-1 and -2 towards different mutp53. In fact, unlike SLMP53-1 [12], SLMP53-2 was
able to activate mutp53-Y220C, not significantly interfering with mutp53-R280K activity (Figure 1B).
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transfected with pcDNA3 expressing different mutp53 or empty vector, were determined by SRB 
assay after 48h treatment with 3.12–50 µM SLMP53-2; data are mean ± SEM (n = 5); values significantly 
different from pcDNA3-Empty: * p < 0.05, one-way ANOVA with Dunnett’s multiple comparison test. 
Mutp53 expression was confirmed by western blot; GAPDH was used as a loading control. 
Immunoblots represent one of three independent experiments. 
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activity of SLMP53-2 against non-tumoral HFF-1 cells (IC50 of 50 µM) was significantly lower 
compared to tumor cells (Figure 2A). 
In HuH-7 cells, SLMP53-2 displayed a concentration-dependent growth inhibitory effect on 
colony formation (Figure 2C). We next assessed whether the growth inhibitory effect of SLMP53-2 in 
HuH-7 cells was associated with DNA damage. However, unlike the positive control (50 µM 
etoposide), no induction of H2AX phosphorylation (γH2AX) was detected after 14, 28, or 42 µM 
SLMP53-2 treatments (Figure 2D). Consistently, 14 µM SLMP53-2 did not promote mutp53 
phosphorylation at Ser15 (Figure 2E), which is a major p53 phosphorylation site in response to 
genotoxic stresses [14]. 
A microarray analysis (GSE124021) indicated that 28 and 42 µM SLMP53-2 led to the differential 
expression of more than 700 genes (four replicates for each treatment and DMSO (dimethyl sulfoxide) 
control, adjusted p value < 0.05, log2 fold change >0.6 and <−0.6) in HuH-7 cells (Table S1, Figure S1 
and Figure S2). Pathway and upstream regulator analyses (Ingenuity Pathway, Metascape and 
Enrichr) identified signatures consistent with downregulation of cell cycle progression, upregulation 
of lipid metabolism and cell death, and ER stress induction (Figure 2F–H, Figure S1, Figure S2 and 
Table S2). In SLMP53-2-treated HuH-7 cells, NUPR1, TP53 and ATF4 were among the top scoring 
Figure 1. Growth inhibitory effect of SLMP53-2 in human tumor cells is dependent on structural
mutp53. (A) Chemical synthesis of SLMP53-2. (B) IC50 values of SLMP53-2, in p53-null H1299 cells
transfected with pcDNA3 expressing different mutp53 or empty vector, were determined by SRB assay
after 48h treatment with 3.12–50 µM SLMP53-2; data are mean ± SEM (n = 5); values significantly
different from pcDNA3-Empty: * p < 0.05, one-way ANOVA with Dunnett’s multiple comparison
test. Mutp53 expression was confirmed by western blot; GAPDH was used as a loading control.
Immunoblots represent one of three independent experiments.
For an in-depth analysis of the molecular mechanism of SLMP53-2, we focused on mutp53-Y220C,
which is known to have a druggable hydrophobic pocket [13]. First, the growth inhibitory effect of
SLMP53-2 against HuH-7 and HCC1419 cells endogenously expressing mutp53-Y220C was evaluated
by SRB assay. As expected, SLMP53-2 inhibited the growth of both tumor cells with similar IC50 values
(Figure 2A), and higher potency than APR-246 (Figure 2B). Notably, the growth inhibitory activity of
SLMP53-2 against non-tumoral HFF-1 cells (IC50 of 50 µM) was significantly lower compared to tumor
cells (Figure 2A).
In HuH-7 cells, SLMP53-2 displayed a concentration-dependent growth inhibitory effect on colony
formation (Figure 2C). We next assessed whether the growth inhibitory effect of SLMP53-2 in HuH-7
cells was associated with DNA damage. However, unlike the positive control (50 µM etoposide),
no induction of H2AX phosphorylation (γH2AX) was detected after 14, 28, or 42 µM SLMP53-2
treatments (Figure 2D). Consistently, 14 µM SLMP53-2 did not promote mutp53 phosphorylation at
Ser15 (Figure 2E), which is a major p53 phosphorylation site in response to genotoxic stresses [14].
A microarray analysis (GSE124021) indicated that 28 and 42 µM SLMP53-2 led to the differential
expression of more than 700 genes (four replicates for each treatment and DMSO (dimethyl sulfoxide)
control, adjusted p value < 0.05, log2 fold change >0.6 and <−0.6) in HuH-7 cells (Table S1, Figures S1
and S2). Pathway and upstream regulator analyses (Ingenuity Pathway, Metascape and Enrichr)
identified signatures consistent with downregulation of cell cycle progression, upregulation of lipid
metabolism and cell death, and ER stress induction (Figure 2F–H, Figures S1 and S2 and Table S2).
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In SLMP53-2-treated HuH-7 cells, NUPR1, TP53 and ATF4 were among the top scoring upstream
regulators inferred from the gene expression dataset. NUPR1 is an ATF4 target and can contribute to ER
stress responses, cell proliferation and apoptosis [15]. Gene expression changes showed that most ATF4
target genes were upregulated, while the majority of NUPR1 targets were downregulated (Figure 2H).
This was expected as several NUPR1 targets are involved in cell cycle and proliferation. Interestingly,
downregulated genes were enriched for targets of miR-34a (Figure S2), which is a well-established
p53-inducible microRNA [16]. Gene expression changes identified by microarray analysis were
confirmed by qPCR for selected genes (Figure S2). The gene expression signature had similarities with
molecules inducing apoptosis, autophagy or inhibiting the proteasome, based on Connectivity Map
(Figure S3 and Table S3).
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and endoplasmic reticulum (ER) stress. (A) Concentration-response cu ves for SLMP53-2 in human
no -tumoral HFF-1 and tumor mutp53-Y220C-expressing HuH-7 and CC1419 cells, analyzed by
sulforho amine B (SRB) assay after 48 h treatment with 3.12–50 µM SLMP53-2. Data are mean ± SEM
(n = 5); * p < 0.05, extra sum-of-squares F test. (B) IC50 values of SLMP53-2 and APR-246 in HuH-7 and
HCC1419 cells were determined by SRB assay after 48 h treatment with 3.12–50 µM SLMP53-2 or APR-246.
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Data are mean ± SEM (n = 5); * p < 0.05, two-way ANOVA with Sidak’s multiple comparison test.
(C) Effect of SLMP53-2 in HuH-7 cell colony formation, analyzed after 14 days incubation with
SLMP53-2; a representative experiment is shown. Data are mean ± SEM (n = 5); values significantly
different from DMSO: * p < 0.05, one-way ANOVA with Dunnett’s multiple comparison test. (D) Levels
of γH2AX in HuH-7 cells treated with SLMP53-2; 50 µM etoposide was used as a positive control
(PC). (E) Levels of mutp53 phosphorylation at Ser15 in HuH-7 cells treated with 14 µM SLMP53-2.
In (D,E), immunoblots represent one of three independent experiments; glyceraldehyde 3-phosphate
dehydrogenase (GAPDH) was used as a loading control. (F) Top enriched biological pathways grouped
by broad categories based on Ingenuity Pathway Analysis (IPA) starting from the dataset of differentially
expressed genes (DEGs) from HuH-7 cells treated with 28 µM SLMP53-2. The number of features for
each functional annotation is given in parenthesis. The score combines the log10 p-value and predicted
pathway activation or repression status of the corresponding pathway/process, respectively for positive
and negative score. The different colors correspond to the different functional annotation categories.
(G) Top scoring upstream regulators inferred from the same gene expression dataset. The score is the
log10 p-value of the predicted activation status. (H) Gene expression changes of NUPR1 (blue) and
ATF4 (yellow) target genes in SLMP53-2-treated HuH-7 cells.
In accordance with microarray data, 14 and 28 µM SLMP53-2 induced G0/G1-phase cell cycle
arrest (Figure 3A) and apoptosis (Figure 3B), in HuH-7 cells. Moreover, consistently with the induction
of an ER stress response, 28 µM SLMP53-2 increased the levels of XBP1 nuclear protein (Figure 3C and
Figure S4), spliced XBP1 (sXBP1) mRNA (Figure 3D), and phosphorylated eIF2α (Figure 3E).
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Figure 3. ro th inhibitory effect of SL P53-2 in hepatocellular carcino a ( CC) cells is associated
ith cell cycle arrest, apoptosis, and ER stress. (A) Effect of SL P53-2 on cell cycle progression of
HuH-7 cells after 48 h treatment; values significantly different from DMSO: * p < 0.05, two-way ANOVA
with Dunnett’s multiple comparison test. (B) Effect of SLMP53-2 on apoptosis of HuH-7 cells, after 72 h
treatment. Data are mean ± SEM (n = 5); values significantly different from DMSO: * p < 0.05, one-way
ANOVA with Dunnett’s multiple comparison test. (C) Quantification of nuclear fluorescence intensity
of XBP1 in HuH-7 cells after 24 h treatment with 28 µM SLMP53-2. Data are mean ± SEM (n = 3); values
significantly different from DMSO: * p < 0.05, unpaired Student’s t-test. (D) mRNA levels of spliced
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(sXBP1), unspliced (uXBP1), and total XBP1 (tXBP1) in HuH-7 cells after 24 h treatment with 28 µM
SLMP53-2, determined by RT-qPCR; fold of induction is relative to DMSO. Data are mean ± SEM
(n = 3); values significantly different from DMSO: * p < 0.05, two-way ANOVA with Dunnett’s multiple
comparison test. (E) Protein levels of phosphorylated and total eIF2α in HuH-7 cells, after 24 h treatment
with 28 µM SLMP53-2. Immunoblots represent one of three independent experiments; α-actinin was
used as a loading control.
2.2. SLMP53-2 Restores WT-Like Conformation and Transcriptional Activity to mutp53-Y220C in HCC Cells
We next evaluated the effect of SLMP53-2 on the expression levels of several p53 target genes.
By western blot, it was observed that 14 µM SLMP53-2 increased the protein levels of MDM2, p21,
GADD45, BAX, and KILLER, while downregulating survivin and VEGF, in HuH-7 cells, an effect
abolished in HuH-7 p53KO cells (Figure 4A). It is of note that in mutp53-Y220C-expressing HCC1419
cells, 14 µM SLMP53-2 also interfered with the protein levels of several p53 target genes, increasing
MDM2, p21, and KILLER, and decreasing survivin and VEGF (Figure S5).
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Figure 4. SLMP53-2 induces p53 transcriptional targets, including miR-34a and genes involved in ER
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three independent experiments; GAPDH was used as a loading control. (B) mRNA levels of p53 target
genes, in HuH-7 cells, after 24 h treatment with 14 and 28 µM SLMP53-2, determined by RT-qPCR; fold
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of induction is relative to DMSO. (C) miR-34a levels in parental and p53KO HuH-7 cells, after 24 h
treatment with 28 µM SLMP53-2, determined by RT-qPCR; fold of induction is relative to DMSO.
(D) mRNA levels of genes involved in the ER stress response, in parental and p53KO HuH-7 cells,
after 24 h treatment with 28 µM SLMP53-2, determined by RT-qPCR; fold of induction is relative to
DMSO. (E) Analysis of the occupancy of mutp53-Y220C on the p21 promoter in HuH-7 cells, determined
by ChIP, after 24 h treatment with 28 µM SLMP53-2 or DMSO; immunoprecipitation was performed
with an anti-p53 antibody (p53) or an anti-mouse IgG as a negative control (IgG); the enrichment of
DNA fragments was analyzed by RT-qPCR using site-specific primers. In A–E, data are mean ± SEM
(n = 3); values significantly different from DMSO (B–E): * p < 0.05, two-way ANOVA with Dunnett’s
(B,E) or Sidak’s (D) multiple comparison test; * p < 0.05, unpaired Student’s t-test (C).
In HuH-7 cells, the regulation of p53 target genes by 14 and 28µM SLMP53-2 was further confirmed
at mRNA level with the upregulation of BAX, GADD45, CDKN1A (p21), and TNFRSF10B (KILLER),
and the downregulation of BIRC5 (survivin) (Figure 4B). Consistently with the microarray analysis,
28 µM SLMP53-2 also upregulated miR-34a in HuH-7, but not in HuH-7-p53KO cells (Figure 4C).
Moreover, 28µM SLMP53-2 significantly enhanced the expression of p53 target genes involved in the ER
stress response, namely CHOP and DDIT4, as well as of TRB3 (a CHOP target gene [17–19]) in HuH-7,
but not in HuH-7-p53KO cells (Figure 4D). The reestablishment of mutp53-Y220C transcriptional
activity was further supported by chromatin immunoprecipitation (ChIP). In fact, 28 µM SLMP53-2
significantly increased mutp53-Y220C occupancy at the p21 promoter (Figure 4E), reflecting the
restoration of p53 DNA-binding ability.
As a structural mutp53, we investigated the ability of SLMP53-2 to restore wt-like folding
to mutp53-Y220C, through immunoprecipitation (IP) using PAb1620 (wt/folded) and PAb240
(mut/unfolded) conformation-specific antibodies. The results showed that 42 µM SLMP53-2 visibly
increased the amount of p53 precipitated with PAb1620, while decreasing the amount of p53 precipitated
with PAb240 (Figure 5A). Consistently, 42 µM SLMP53-2 visibly increased PAb1620 and decreased
PAb240 immunofluorescence staining in HuH-7 cells (Figure S6).
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immunoblotting with anti-p53 (DO-1) or anti-Hsp70 antibodies; whole cell lysate (input).
Of note that labelling with PAb1620 in DMSO-treated cells may be explained by mutp53-Y220C
temperature-sensitivity [20]. (B) Co-immunoprecipitation of Hsp40, Hsp70, and Hsp90 with p53
in HuH-7 cells treated with 28 and 42 µM SLMP53-2 or DMSO for 36 h, using anti-p53 antibody
(DO-1), followed by immunoblotting with anti-Hsp40, anti-Hsp70, anti-Hsp90, and anti-p53 antibodies;
whole cell lysate (input). (C) Effect of SLMP53-2 in the cell colony formation of HuH-7 cells transfected
with siRNA against Hsp70 (siHsp70) or control siRNA (siCTRL), analysed after 14 days incubation with
SLMP53-2; a representative experiment is shown. Data are mean ± SEM (n = 5); values significantly
different from siCTRL: * p < 0.05, one-way ANOVA with Dunnett’s multiple comparison test. In (A,B),
immunoblots represent one of three independent experiments; GAPDH was used as a loading control.
2.3. Hsp70 is a Potential Mediator of mutp53-Y220C Reactivation by SLMP53-2
To determine the mechanism by which SLMP53-2 would affect mutp53-Y220C function, we checked
whether SLMP53-2 could bind to this mutp53. However, despite the presence of a druggable
hydrophobic pocket in mutp53-Y220C, no binding of SLMP53-2 to recombinant mutp53-Y220C
DBD was detected by heteronuclear single-quantum coherence (HSQC)-NMR (Figure S7).
Chaperones from the Hsp40, Hsp70, and Hsp90 families have long been recognized as
mutp53-binding partners capable of folding mutp53 to the wt-like conformation [21–23]. Therefore,
we interrogated whether SLMP53-2 could reactivate mutp53-Y220C by promoting its interaction with
these chaperones. To investigate potential interactions between mutp53-Y220C and Hsp40/Hsp70/
Hsp90, co-immunoprecipitation (co-IP) experiments were performed in HuH-7 cells. Conversely
to that observed with Hsp40 and Hsp90, 42 µM SLMP53-2 visibly increased the amount of Hsp70
precipitated with p53 (Figure 5B), indicating an enhancement of Hsp70 binding to p53. Moreover,
in Hsp70 siRNA silenced HuH-7 cells (Figure S8), the inhibitory effect of SLMP53-2 on colony formation
was significantly reduced (Figure 5C). Therefore, SLMP53-2 may restore wt-like conformation to
mutp53-Y220C through enhancement of its interaction with Hsp70.
2.4. SLMP53-2 Sensitizes HCC Cells to Sorafenib
A potential synergistic association between SLMP53-2 and sorafenib was assessed by SRB assay,
in HuH-7 cells. When combined with 1.5 µM SLMP53-2, sorafenib displayed significantly higher
growth inhibitory effect compared to its effect as a single agent (Figure 6A). Consistently, a synergistic
effect (CI < 1) was obtained for all tested sorafenib concentrations in combination with 1.5 µM SLMP53-2
(Figure 6B).
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Figure 6. SLMP53-2 synergizes with sorafenib in HCC cells. HuH-7 cells were treated with increasing
concentrations of sorafenib, alone and in combination with 1.5 µM SLMP53-2. (A) Cell growth was
measured by SRB assay after 48 h treatment; growth obtained with control (DMSO) was set as 100%.
Data are mean ± SEM (n = 4); values significantly different from chemotherapeutic alone: * p < 0.05,
two-way ANOVA. (B) Combination index (CI) values calculated using the CompuSyn software for
each combined treatment. CI < 1, synergy; 1 < CI < 1.1, additive effect; CI > 1.1, antagonism. CI values
were calculated using a mean value effect (n = 4).
2.5. SLMP53-2 Displays In Vivo Anti-Tumor Activity in HCC Xenograft Mouse Models, with No Apparent
Toxic Side Effects
The toxicity profile of SLMP53-2 was evaluated in Wistar rats subjected to five intraperitoneal
administrations of 50 mg/kg SLMP53-2 or vehicle, followed by analysis of hematological and biochemical
parameters from blood samples (Table S4). Although a slight reduction of the red cell distribution
width and mean platelet volume was observed upon SLMP53-2 treatment, these values were within the
reference range [24]. Therefore, no undesirable hematological and biochemical toxicity was induced by
SLMP53-2 in vivo.
To evaluate the in vivo anti-tumor activity of SLMP53-2, five intraperitoneal administrations of
50 mg/kg SLMP53-2 or vehicle were performed in nude mice carrying HuH-7 xenografts. A pronounced
reduction of tumor volume (Figure 7A) and weight (Figure 7B) was observed in SLMP53-2-treated mice
compared to vehicle. Moreover, nude mice showed no significant variation of body weight throughout
the experiment (Figure 7C), and no significant differences were observed between the weight of spleen,
liver, heart, and kidneys of SLMP53-2-treated mice and vehicle (Figure 7D). These results further
supported a favorable therapeutic index of SLMP53-2 in vivo. Additionally, the immunohistochemistry
(IHC) staining of tumor sections revealed that SLMP53-2 decreased Ki-67 and VEGF, and increased
BAX staining (Figure 7E–G), compared to vehicle. Altogether, these results unveiled a potent in vivo
anti-tumor activity of SLMP53-2 through induction of apoptosis and inhibition of cell proliferation
and angiogenesis.
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xenograft tumor tissues treated with SLMP53-2 or vehicle; in (F), quantification of the number of Ki-67
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3. Discussion
The advances in understanding cancer pathobiology have supported the crucial role of mutp53
in all hallmarks of cancer, rendering mutp53 reactivation one of the most promising therapeutic
strategies in cancer treatment. The reactivation of mutp53 also poses a great opportunity in combination
therapy with conventional chemotherapies known to trigger cancer cell death through an active
p53-dependent pathway. Nonetheless, drugging mutp53 has shown to be a challenging task, with no
mutp53 reactivators still available for clinical use. In fact, although the potential of reactivating wt-like
function to mutp53 with canonical genes transcription has been proven, it does not always translate
into halting tumor growth [1,2,4,5].
In this work, we report the identification of SLMP53-2 as a novel reactivator of mutp53,
with p53-dependent growth inhibitory effect on human tumor cells through induction of cell cycle
arrest and apoptosis. Interestingly, SLMP53-2 stimulates the ER stress response by inducing the
expression of several ER stress markers, including the p53-target gene CHOP, which triggers ER
stress-related cell death [25]. ER stress occurs when the tightly-regulated protein folding environment
of the ER is disrupted, causing accumulation of unfolded proteins. This triggers the unfolded protein
response (UPR), a mechanism intended to re-establish ER homeostasis. When the UPR fails to restore
ER homeostasis, cell death is triggered [25]. In fact, ER stress exacerbation for cell death induction has
been proposed as a relevant anticancer therapeutic strategy, specifically against HCC [26]. Particularly,
the prodrug of thapsigargin, mipsagargin (a known ER stress inducer through interference with ER
calcium levels) was tested in patients with solid tumors, including HCC [27]. Moreover, zebularine
(a DNA methyltransferase inhibitor) has been reported to induce p53-dependent ER stress-mediated cell
death in colorectal cancer cells [28]. Interestingly, the mutp53 reactivators APR-246 and PK11007 have
also been reported to induce ER stress-mediated cell death in mutp53-expressing tumor cells [29,30].
Herein, SLMP53-2 is also shown to restore wt-like folding and DNA-binding ability to
mutp53-Y220C. In fact, SLMP53-2 reactivates p53 transcriptional activity, regulating the expression
of several p53 transcriptional targets involved in cell cycle arrest (p21, GADD45), apoptosis
(BAX, KILLER, survivin), ER stress response (CHOP, DDIT4), and angiogenesis (VEGF). Interestingly,
SLMP53-2 causes p53-dependent reduction of the expression levels of survivin, which is frequently
overexpressed in HCC, correlating with increased invasion and metastasis, and decreased overall and
relapse-free survival [31–33]. Additionally, SLMP53-2 upregulates miR-34a, a p53 transcriptional target.
Consistently, the microarray data revealed that SLMP53-2 leads to downregulation of several miR-34a
targets. miR-34a is a crucial tumor suppressor that controls cellular processes including proliferation,
apoptosis, senescence, and stemness [34]. This is of particular interest in HCC, in which miR-34a
downregulation is common and frequently associated with invasion and metastasis [35]. Consistently,
MRX34, a liposomal miR-34a mimic, has displayed promising anti-tumor activity in orthotopic HCC
models [36], having recently completed phase I clinical trials for advanced solid tumors, including HCC [37].
Despite its inability to bind to mutp53-Y220C, SLMP53-2 enhances the mutp53-Y220C interaction
with chaperone Hsp70. In fact, Hsp70 is a known mutp53 binding partner, leading to its refolding and
protein stabilization, with subsequent restoration of DNA-binding and transcriptional activity [21–23].
A similar mutp53 reactivation mechanism was recently reported for chetomin, which restores wt-like
function to mutp53-R175H by enhancing its interaction with Hsp40 [38]. Interestingly, the requirement
of Hsp70 for mutp53-R175H stabilization, and its contribution to the pancreatic cells malignant
transformation have been recently reported [39]. However, these observations were conducted in
non-tumoral cells. A cell context-dependence of the Hsp70 effect on mutp53 might justify the distinct
observations made in the current work.
The anti-proliferative effect of SLMP53-2 on p53-null tumor cells ectopically expressing four
prevalent mutp53 forms supports its ability to reactivate structural mutp53 forms, including R175H,
Y220C, and G245S. These results are reinforced by the capability of SLMP53-2 to restore mutp53-Y220C
transcriptional activity in HCC cells endogenously expressing this mutp53. The activation of
mutp53-Y220C transcriptional activity by SLMP53-2 was also evidenced in breast tumor cells expressing
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this mutp53, indicating its potential to reactivate mutp53 in distinct tumor cell types. It is also worth
noting that SLMP53-2 has antitumor activity against wtp53-expressing tumor cells, namely HCC
HepG2 cells (IC50 of 12.5 ± 0.8 µM; Figure S10A). In fact, a wtp53-dependent growth inhibitory effect
could be evidenced for SLMP53-2, which showed a two-fold reduction in the IC50 value in HCT116
colon tumor cells expressing wtp53 (IC50 of 8.4 ± 1.1 µM) compared to its isogenic p53-null derivative
(IC50 of 17.7 ± 2.3 µM) (Figure S10B). This is consistent with the proposed mechanism of action of
SLMP53-2, since the stabilization of wtp53 by Hsp70 has also been reported [22].
In our previous work, SLMP53-1 was identified as a reactivator of mutp53 [12]. Despite being
chemical derivatives, several structural differences can be found between SLMP53-1 and -2. In particular,
SLMP53-2 has a phenyl instead of a methyl group in position 9b, and its indole nitrogen is protected
with a methyl group. It is well-known that small structural modifications can completely change the
activity of a compound on a specific target, since with the introduction of a certain group, the compound
may no longer fit into the pocket of the target protein losing its activity. Moreover, it is currently
accepted that structurally related drugs often act against distinct targets. In fact, only a small number
of drugs that share the same or overlapping targets are structurally related [39]. As such, although
both SLMP53-1 and -2 act as mutp53 reactivators, the inability of SLMP53-1 to reactivate the structural
mutp53-Y220C, having effect on contact mutp53-R280K, allow us to predict a distinct mechanism of
mutp53 reactivation. This hypothesis is supported by the inability of SLMP53-1 to enhance the Hsp70
interaction with mutp53-Y220C in HuH-7 cells (Figure S11), and it may explain their capability to
reactivate distinct mutp53, as well as their distinct growth inhibitory activity towards tumor cells.
Considering the relevance of mutp53 in the HCC pathogenesis and the lack of therapeutic alternatives
for this cancer [10,11], this work also paves the way to a potential application of SLMP53-2 (alone or
in combination therapy) in HCC treatment. Moreover, besides its growth inhibitory activity against
HCC cells (superior to that of APR-246, currently in phase Ib/II clinical trials [5]), SLMP53-2 also
sensitizes HCC cells to sorafenib, the only drug currently approved for the treatment of advanced
HCC [8,9]. Importantly, in the HCC xenograft mouse model, SLMP53-2 displays pronounced antitumor
activity associated with induction of apoptosis and inhibition of cell proliferation and angiogenesis.
Interestingly, the crucial role of angiogenesis in HCC development and dissemination has been widely
explored for the development of targeted therapies [40]. In fact, antiangiogenic agents, like sorafenib,
have been the only targeted drugs with positive results in clinical trials for HCC [40]. Notably, SLMP53-2
also displays a favorable in vivo toxicological profile, with no significant alteration of toxicological
parameters related to liver function. This is of particular importance in HCC, as patients often display
liver cirrhosis that can lead to impaired liver function and consequently increased drug toxicity [41].
4. Materials and Methods
4.1. Compounds and Antibodies
Sorafenib, etoposide, and APR-246 were purchased from Santa Cruz Biotechnology (Heidelberg,
Germany), Calbiochem (VWR, Carnaxide, Portugal), and Sigma-Aldrich (Sintra, Portugal), respectively.
All antibodies are listed in Table S5.
4.2. Chemical Synthesis of SLMP53-2
4.2.1. General Methods
All reagents and solvents were obtained from commercial suppliers and used without further
purification. Reactions were performed under a nitrogen atmosphere. Melting point was determined
using a Kofler camera Bock monoscope M (Lisboa, Portugal). Thin layer chromatography was performed
using silica gel 60 F254 plates (Merck, Darmstadt, Germany) and visualized by ultraviolet (UV) light.
For flash column chromatography high purity grade Merck silica gel (200–400 mesh) was used. 1H- and
13C-NMR spectra were recorded on a Fourier 300 Avance instrument (Bruker, Fällanden, Zurich,
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Switzerland) at 300 MHz (1H-NMR) and at 75 MHz (13C-NMR). 1H- and 13C-NMR chemical shifts are
reported in parts per million (ppm, δ) referenced to the solvent used. Proton coupling constants (J)
are expressed in hertz (Hz). Multiplicities are given as: s (singlet), dd (doublet of doublet), and m
(multiplet). The specific rotation value was measured at r.t. on a 241 MC polarimeter (PerkinElmer,
Waltham, MA, USA; New University of Lisbon, PT). Compound SLMP53-2 showed purity ≥90% by
LC-MS, performed in an Alliance 2695 HPLC system (Waters, Dublin, Ireland) equipped with a Waters
SunFire C18 column (100 × 2.1 mm; 5 µM) at 35 ◦C, using as mobile phase a gradient from 95% solution
A (Milli-Q water containing 0.5% formic acid (v/v)) to 95% solution B (acetonitrile), and employing
a photodiode array detector to scan wavelength absorption from 210 to 600 nm; MS experiments
were performed on Micromass® Quattro Micro triple quadrupole (Waters®, Dublin, Ireland) with
an electrospray in positive ion mode (ESI+), ion source at 120 ◦C, capillary voltage of 3.0 kV and
source voltage of 30 V, at the Liquid Chromatography and Mass Spectrometry Laboratory, Faculty of
Pharmacy, University of Lisbon.
4.2.2. Chemical Synthesis of SLMP53-2
Compound 1 was prepared from (S)-tryptophanol (0.16 g, 0.84 mmol, 1.0 equivalent) and
2-benzoyl-benzoic acid (0.21 g, 0.93 mmol, 1.1 equivalent) in 10 mL of toluene, according to the
protocol described in reference [42]. To a stirred solution of compound 1 (0.10 g, 0.26 mmol) in
anhydrous DMF (3 mL) at 0 ◦C, and under inert atmosphere of nitrogen, 0.014 g of NaH (0.58 mmol,
2.2 equivalent, 95% anhydrous reagent) was added. After stirring for 30 min, 0.025 mL of methyl
iodide (0.39 mmol, 1.5 equivalent) was added and the reaction was slowly allowed to warm to room
temperature for 1 h. Ethyl acetate (10 mL) was added, and the organic phase washed with water
(6 × 10 mL), with an aqueous saturated solution of NaHCO3 and then with a brine solution. The organic
phase was dried with Na2SO4 and concentrated. After flash chromatography (ethyl acetate/n-hexane
1:1) and recrystallization from EtOAc, SLMP53-2 was obtained as a white crystalline solid (0.096 g,
89.3%); mp: 134–136 ◦C; [α]20D = + 84.5 (c = 0.37, CH2Cl2). 1H-NMR (CDCl3) δ 7.84–7.77 (m, 1H,
ArH), 7.67–7.59 (m, 2H, ArH), 7.53–7.45 (m, 3H, ArH), 7.42–7.35 (m, 3H, ArH), 7.22 (m, 3H, ArH),
7.12–7.05 (m, 1H, ArH), 6.96 (s, 1H, ArH), 4.69 (m, 1H, H-3), 4.46 (dd, J = 8.6, 7.6 Hz, 1H, H-2), 3.98
(dd, J = 8.6, 6.8 Hz, 1H, H-2), 3.72 (s, 3H, NCH3), 3.21 (dd, J = 14.7, 5.5 Hz, 1H, CH2-indole), 2.65 (dd,
J = 14.7, 9.3 Hz, 1H, CH2-indole); 13C-NMR (CDCl3) δ 174.72 (C = O), 147.29 (Cq), 138.98 (Cq), 136.98
(Cq), 133.38 (ArCH), 131.22 (Cq), 130.20 (ArCH), 128.87 (ArCH), 128.76 (ArCH), 128.01 (Cq), 127.01
(CH-indole), 125.92 (ArCH), 124.48 (ArCH), 123.56 (ArCH), 121.75 (ArCH), 119.01 (ArCH), 110.29 (Cq),
109.26 (ArCH), 101.06 (C-9b), 76.43 (CH-2), 55.91 (CH-3), 32.77 (N-CH3), 30.15 (CH2-indole); MS (ESI)
m/z calcd for C26H22N2O2: 394, found 395 [M + H]+.
4.3. Human Cell Culture Conditions
Human non-small cell lung carcinoma NCI-H1299, breast ductal carcinoma HCC1419,
and non-tumorigenic foreskin fibroblast HFF-1 cell lines were purchased from ATCC (Rockville,
MD, USA). The human HCC HuH-7 cell line was purchased from the JCRB cell bank (Osaka, Japan).
The p53 knock-out (KO) HuH-7 cell line was generated using CRISPR editing [43]. Tumor cells were
cultured in RPMI-1640 medium with UltraGlutamine (Lonza, VWR, Basel, Switzerland) with 10%
FBS (Gibco, Alfagene, Lisboa, Portugal). HFF-1 cells were cultured in DMEM:F12 (Lonza) with 10%
FBS. Cells were maintained in a humidified incubator at 37 ◦C with 5% CO2. Routine testing for
Mycoplasma was performed using the MycoAlert™ PLUS detection kit (Lonza).
4.4. Transfection, Cell Proliferation, and Combination Therapy Assays
4.4.1. Construction of Mammalian Expression Vectors
The full-length coding sequences of mutp53 were PCR-amplified from pLLS89 yeast vectors
(kindly provided by Dr Gilberto Fronza, from IST Istituto Nazionale per la Ricerca sul Cancro, Italy)
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with Vent DNA polymerase (New England Biolabs, Werfen, Porto, Portugal), using the primers pair
5′ GGG GTA CCA TGG AGG AGC CGC AGT CAG 3′ and 5′ CCG CTC GAG TCA GTC TGA GTC
AGG CCC TTC 3′, where the restriction sites for KpnI/XhoI (in bold) were included, respectively.
The PCR products and the mammalian expression vector pcDNA3 (Invitrogen, Alfagene, Lisbon,
Portugal) were digested with KpnI/XhoI (New England Biolabs, Werfen, Carnaxide, Portugal), purified
from agarose gel, and ligated with T4 DNA ligase (Promega, VWR, Carnaxide, Portugal), originating
the expression vectors pcDNA3-mutp53. These constructs were propagated in NZY5α Escherichia
coli cells (NZYTech, Lisbon, Portugal). The sequence of each mutp53 in the constructed vectors was
confirmed by sequencing (Eurofins GATC Biotech, Konstanz, Germany) with specific pcDNA3 primers.
pcDNA3-mutp53 vectors were extracted using the PureYield™ Plasmid Miniprep System kit (Promega,
VWR, Carnaxide, Portugal).
4.4.2. Transfection
For ectopic mutp53 expression, p53-null NCI-H1299 cells were transfected with the previously
obtained pCDNA3 plasmid encoding mutp53-R175H, -Y220C, -G245S, or -R280K, or empty pCDNA3.
For Hsp70 knockdown, HuH-7 cells were transfected with ON-TARGETplus Human HSPA1A
(3303) siRNA SMARTpool or nonspecific siRNAs (Non-targeting Pool) (Dharmacon, Bioportugal,
Porto, Portugal). Cells in suspension were transfected using the ScreenFectA reagent and seeded
immediately [44].
4.4.3. SRB Assay
5.0 × 103 (HuH-7, NCI-H1299) or 1.0 × 104 (HCC1419, HFF-1) cells/well were seeded in 96-well
plates and allowed to adhere overnight, followed by treatment with serial dilutions of compounds.
Cell proliferation was measured as described [45]. IC50 values were determined using the GraphPad
Prism software v7.0 (La Jolla, CA, USA). In combination therapy assays, combination index (CI) values
were determined using the CompuSyn software v1.0 (ComboSyn, Inc., Paramus, NJ, USA) [46,47].
4.4.4. Colony Formation Assay
2.0 × 103 HuH-7 cells/well were seeded in 6-well plates and immediately treated with 0.88–28 µM
SLMP53-2. Colonies were fixed and stained after 14 days, as described [47]. Colonies with more than
20 cells were counted.
4.5. Cell Cycle and Apoptosis Analysis
1.5 × 105 HuH-7 cells/well were seeded in 6-well plates and allowed to adhere overnight, followed
by treatment with 14 or 28 µM SLMP53-2 or DMSO for 48 h (cell cycle) or 72 h (apoptosis). Cell cycle
and apoptosis were analyzed as described [45], using the Accuri™ C6 flow cytometer and the BD
Accuri C6 software (BD Biosciences, Enzifarma, Porto, Portugal). FlowJo v10.0.7 (Treestar, Ashland,
OR, USA) was used for quantification of cell cycle phases.
4.6. Western Blot
1.5 × 105 HuH-7 or NCI-H1299 cells/well were seeded in 6-well plates and allowed to
adhere overnight, followed by treatment with 14 µM SLMP53-2. Sample preparation and western
blot were performed as described [48]. Signal detection was carried out using the ECL Prime
Amersham kit (GE Healthcare, VWR, Carnaxide, Portugal) and the ChemiDoc™ MP Imaging System
(Bio-Rad Laboratories, Amadora, Portugal). Whole blot images (Figure S12) and blot quantifications
(Table S7) are provided in supplementary material.
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4.7. IP and co-IP
2 × 106 HuH-7 cells were seeded in 75 cm2 flasks, allowed to adhere overnight, followed by
36 h treatment with 28 or 42 µM SLMP53-2 or DMSO. The Pierce Classic Magnetic IP/Co-IP Kit
(Thermo Scientific, Dagma, Carcavelos, Portugal) was used according to manufacturer’s instructions.
For IP, 1 µg/mL PAb1620 (wt/folded) or PAb240 (mut/unfolded) conformation-specific anti-p53
antibodies were used. For Co-IP, 1 µg/mL anti-p53 antibody was used. Hsp40/Hsp70/Hsp90, p53,
and GAPDH (loading control) were detected by western blot, in immunoprecipitated fractions and
whole cell lysates (input), as described above.
4.8. RNA Extraction and RT-qPCR
1.5 × 105 HuH-7 cells/well were seeded in 6-well plates and allowed to adhere overnight, followed
by 24 h treatment with 14 or 28 µM SLMP53-2 or DMSO.
4.8.1. Gene Expression Analysis
Total RNA extraction and RT-qPCR were performed as described [49], using specific primers
for each analyzed gene (Table S6) (Eurofins, MWG, Milan, Italy); GAPDH and B2M were used as
reference genes.
4.8.2. miRNA Analysis
Total RNA was extracted using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) according to
manufacturer’s instructions. RNA concentration and purity were measured in NanoDrop™ 1000
(Thermo Fisher Scientific, Waltham, MA, USA). 260/280 nm and 260/230 nm ratios ranged around 1.8–2.2.
RNA integrity was assessed by gel electrophoresis. miRNA levels were evaluated using TaqMan
miRNA assays (Applied Biosystems, Foster City, CA, USA). cDNA was synthesized (MyCycler Thermal
Cycler, Bio-Rad) using RNA, TaqMan MicroRNA Reverse Transcription Kit (Applied Biosystems) and
stem-loop Reverse Transcription primers (hsa-miR-34a-5p; Applied Biosystems). qPCR reactions were
performed in CFX96 Touch™ Real-Time PCR Detection System (Bio-Rad) using cDNA, miR-34a or
snRNA U6 TaqMan probes (Applied Biosystems) and SsoAdvanced™ Universal Probes Supermix
(Bio-Rad, Hercules, CA, USA). snRNA U6 was used as reference gene. Relative expression levels were
calculated using the quantification cycle (Cq) method, according to MIQE guidelines [50].
4.9. ChIP
1.5 × 106 HuH-7 cells were seeded in 150 mm dishes and allowed to adhere overnight, followed
by 24 h treatment with 28 µM SLMP53-2 or DMSO. ChIP protocol was performed as described [51].
p53 occupancy at the p21 promoter was measured by RT-qPCR (primers are listed in Table S6).
4.10. Microarray Experiments
2.0 × 106 HuH-7 cells were seeded in 6-well plates and allowed to adhere overnight, followed
by 24 h treatment with 28 or 42 µM SLMP53-2 or DMSO. Total RNA was extracted using Illustra™
RNAspin Mini (GE Healthcare, Chicago, IL, USA), purity and concentration were measured by
Nanodrop and Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA). Samples with
RIN (RNA integrity number) ≥8 were used for the one-Color Microarray-Based Gene Expression
Analysis protocol (Agilent Technologies, Santa Clara, CA, USA) and hybridized on Agilent-014850
4x44K Whole Human Genome Microarrays. Slides were scanned on the Agilent DNA Microarray
Scanner (G2505C) using the Agilent HD_GX_1Color Profile of Agilent ScanControl v8.1.3 (Agilent
Technologies, Santa Clara, CA, USA). Four biological replicates per treatment were prepared and
analyzed. Microarray data have been deposited in Gene Expression Omnibus database (GSE124021).
The scanned TIFF images were analyzed numerically and background-corrected using the Agilent
Feature Extraction Software v10.7.7.1 (Agilent Technologies, Santa Clara, CA, USA), according to the
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Agilent GE1_107_Sep09 standard protocol. The output of Feature Extraction was analyzed with the
R software environment for statistical computing (http://www.r-project.org/) and the Bioconductor
packages (http://www.bioconductor.org/). The array Quality Metrics package was used to check the
quality of the arrays. Low signal Agilent probes, identified by a repeated “not detected” flag across the
majority of the arrays in every condition, were filtered out from the analysis. Signal intensities across
arrays were background corrected (Edwards method) and normalized with the quantile normalization
method. DEGs were determined using a double threshold based on: (1) the magnitude of the
change (fold change greater than ± 2); (2) the statistical significance of the change, measured with
a multiple-test-correction adjusted p-value less than 0.05 using limma package. The IPA (v2017)
resource was used for enrichment analysis of the transcriptome DEGs lists. The IPA Ontologies are
derived from manually curated collections of experimental data and are utilized to infer functional
enrichment of different type of relationships. The significance of gene list over-representations was
determined using a Fisher exact p-value threshold of 0.05 with multiple-test-correction. In particular,
the bio-functions and the up-stream regulators analysis were used. The graphical representation of the
IPA results was performed in R/Bioconductor environment.
4.11. Immunofluorescence
Immunofluorescence staining of HuH-7 cells was performed basically as described [52].
4.11.1. XBP1 Staining
HuH-7 cells were seeded in 24-well plates at 1.5 × 105 cells/well density and allowed to adhere
overnight, followed by 24 h treatment with 28 µM SLMP53-2 or DMSO. After treatments, cells were
fixed with 4% formaldehyde/PBS for 20 min at room temperature (RT), were blocked with BSA 5% and
Triton 0.1% for 1h at RT, incubated with anti-XBP1 antibody overnight at 4 ◦C, followed by incubation
with an Alexa Fluor 488-conjugated secondary antibody for 1 h at RT, and staining with Hoechst
(ThermoFisher Scientific, Waltham, MA, USA; 1:10,000). Images were visualized with a Zeiss Axio
Observer Z1 microscope (Carl Zeiss, Oberkochen, Germany) using Zeiss AxioVision v4.8.1. Nuclear
signal was quantified using CellProfilerTM software v3.1.5 (Broad Institute, Cambridge, MA, USA).
4.11.2. PAb240/PAb1620 Staining
HuH-7 cells were seeded in chambered cell culture slides at 1× 104 cells/well density and allowed to
adhere overnight, followed by 36 h treatment with 42 µM SLMP53-2 or DMSO. After treatment, the cell
monolayer was fixed with 4% formaldehyde/PBS for 30 min at RT, permeabilized with 0.1% Triton for
20 min at 4 ◦C, blocked with 5% BSA for 1h at RT, incubated with PAb240, PAb1620, or DO-1 anti-p53
antibodies overnight at 4 ◦C, followed by incubation with Alexa Fluor 488-conjugated secondary
antibody for 1h at RT, and staining with DAPI. Cells were photographed (Nikon DS-5Mc camera;
Nikon Eclipse E400 fluorescence microscope; Nikon ACT-2U software, Izasa, Carnaxide, Portugal).
4.12. HSQC-NMR
The stabilized DBD of the mutp53-Y220C (T-p53C-Y220C) was expressed and purified as
described [29]. For expression of its 15N-labeled form, M9 minimal medium with 15NH4Cl (1 g/L) as
sole nitrogen source was used.
1H-15N HSQC spectra of 15N-labeled T-p53C-Y220C (70 µM) and different compound
concentrations were recorded and analyzed as described [29]. Briefly, the spectra were recorded
at 293 K on a Bruker Avance-800 spectrometer using a 5-mm inverse cryogenic probe. Compound
samples were mixed with protein immediately before the NMR measurement. Analysis of spectra
was performed using Sparky 3.11430 (San Francisco, CA, USA) and Bruker Topspin 2.0 software
(Coventry, UK).
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4.13. In Vivo Anti-Tumor and Toxicity Assays
All animal experiments were conducted following the EU Directive 2010/63/EU and National
Authorities. The study was approved by the local Animal Welfare Body (Ref. ORBEA-5-2016). Swiss
nude mice (CharlesRiver Laboratories, Barcelona, Spain) were housed under pathogen-free conditions in
ventilated cages. 7.5 × 106 HuH-7 cells (in PBS/Matrigel 1:1; Corning, Enzifarma, Porto, Portugal) were
subcutaneously inoculated in the dorsal flank of female Swiss nude mice (five animals/group). Tumors
were routinely measured using a caliper for calculation of tumor volume by the formula (a × b2)/2
(a and b represent the longest and shortest tumor axes, respectively). Twice-weekly intraperitoneal
injections of 50 mg/kg SLMP53-2 or vehicle were started for tumors with approximately 100 mm3
(5 days after the grafts). Five administrations were performed with continuous monitoring of tumor
volume, animal weight, and signs of morbidity. At the end of treatment, animals were sacrificed by
cervical dislocation. For toxicity assays, female Wistar rats were treated with 50 mg/kg SLMP53-2 or
vehicle (DMSO) by intraperitoneal injection, twice a week. After five administrations, blood samples
were collected for toxicological analysis. Each experimental group was composed of four animals.
4.14. Immunohistochemical (IHC) Analysis
IHC of xenograft tumor tissue was performed as described [49]. Evaluation of DAB intensity and
quantification were performed using ImageJ v1.8.0. (Madison, WI, USA).
4.15. Statistical Analysis
Data were statistically analyzed using the GraphPad Prism software v7.0 (GraphPad Inc., La Jolla,
CA, USA). Appropriate statistical tests were applied to each dataset; p < 0.05 was considered
statistically significant.
5. Conclusions
The present work brings a new mutp53-reactivating compound with a distinct mechanism of
action from those currently reported. Notably, SLMP53-2 may also represent a new hope in cancer
treatment, either alone or in combination therapy, particularly against HCC. In addition, it represents
a lead compound and therefore a valuable starting material for new optimized derivatives. In fact,
this work highlights the tryptophanol-derived oxazoloisoindolinones as a promising chemical family
for the development of more effective anticancer therapeutic options by targeting a larger set of
mutp53 forms.
6. Patents
The compound SLMP53-2 is protected under an international patent (European patent EP3013833
and US patent 20160347765).
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